Influenza Vaccines Market, by Vaccine Type (Trivalent Vaccines and Quadrivalent Vaccines), by Virus Type (Influenza Virus A and Influenza Virus B), by Age Group (Pediatrics and Adults), and by Region (North America, Latin America, Europe, Asia Pacific,

Influenza Vaccines Market, by Vaccine Type (Trivalent Vaccines and Quadrivalent Vaccines), by Virus Type (Influenza Virus A and Influenza Virus B), by Age Group (Pediatrics and Adults), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Influenza is an infection caused by influenza virus and is commonly known as flu. Vaccination for influenza aids in prevention of flu. This vaccine is recommended for children aged 6 months and older. Moreover, according to the World Health Organization (WHO), influenza virus is transmitted primarily by respiratory secretions or droplets of the infected person. It has an annual global attack rate of 5-10% in adults and 20–30% in children. Influenza vaccines are available with a wide range of options for different age groups such as children aged 6 months and above and adults aged 65 and above. According to the Centers for Disease Control and Prevention (CDC), 2021, in the U.S., 1,675 (0.2%) of 818,939 respiratory specimens were tested positive for an influenza virus. There are various type of vaccine type such as the trivalent vaccine (TIV) which contains one influenza B antigens and The Quadrivalent influenza vaccine (QIV) contains two influenza B antigens.

Market Dynamics

Investments by the key players in influenza vaccines market, in order to develop new innovative technologies and to increase production capacity is expected to drive the market growth. For instance, in December 2019, the U.S. Department of Health and Human Services (HHS) announced that it has invested US$ 226 million, a six-year contract, to increase the capacity to produce recombinant influenza vaccine in the U.S. The manufacturing of vaccines will be initiated through a public-private partnership between the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), and Sanofi Pasteur which is pharmaceutical company.

Key features of the study:

• This report provides an in-depth analysis of the global influenza vaccines market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global influenza vaccines market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies
• Key companies covered as a part of this study include Seqirus, GlaxoSmithKline plc, Sanofi, AstraZeneca, FluGen, Inc., Moderna, Inc., Biocryst Pharmaceuticals, Inc., CPL Biologicals Pvt. Ltd., CureVac AG, OSIVAX, and Solaris Vaccines
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global influenza vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global influenza vaccines market

Detailed Segmentation:

• Global Influenza Vaccines Market, by Vaccine Type:
• Trivalent Vaccines
• Quadrivalent Vaccines
• Global Influenza Vaccines Market, by Virus Type:
• Influenza Virus A
• Influenza Virus B
• Global Influenza Vaccines Market, by Age Group:
• Pediatrics
• Adults
• Global Influenza Vaccines Market, By Region:
• North America
• By Country:
• U.S.
• Canada
• Latin America
• By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country:
• U.K.
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe
• Asia Pacific
• By Country:
• Australia
• India
• China
• Japan
• ASEAN
• South Korea
• Rest of Asia Pacific
• Middle East
• By Country:
• GCC
• Israel
• Rest of Middle East
• Africa
• By Country/Region:
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Seqirus *
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• GlaxoSmithKline plc,
• Sanofi,
• AstraZeneca,
• FluGen, Inc.,
• Moderna, Inc.,
• Biocryst Pharmaceuticals, Inc.,
• CPL Biologicals Pvt. Ltd.,
• CureVac AG,
• OSIVAX
• Solaris Vaccines

“*” marked represents similar segmentation in other categories in the respective section.